Current opinion in supportive and palliative care · 2026
Comparison of the EORTC QLQ PR25 and the FACT-P for assessing quality of life in patients with prostate cancer - an updated literature review.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen David, Jomy Jane, Ning Tony, Cheng Samantha, Khan Maira, Bottomley Andrew, Cella David, Chung Hans, Lee Shin Fung, Emmenegger Urban, Hird Amanda, Chow Edward, Wong Henry C Y, Raman Srinivas
Аннотация
PURPOSE OF REVIEW: Prostate cancer can significantly impact psychological, physical, and social well-being. This systematic review compares the development of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Prostate Cancer (EORTC QLQ-PR25) for evaluating quality of life (QoL) in prostate cancer patients, focusing on development, characteristics, reliability, validity, and psychometric properties.
RECENT FINDINGS: Thirteen studies published between 2013 and 2022 met the inclusion criteria. FACT-P and EORTC QLQ-PR25 are both validated, reliable, and responsive instruments for assessing QoL in prostate cancer patients. FACT-P emphasizes emotional, social, and functional well-being alongside prostate-specific concerns, while EORTC QLQ-PR25 focuses on prostate-specific symptoms, particularly urinary, sexual, and hormonal function.
SUMMARY: The FACT-P and EORTC QLQ-PR25 are valid tools for assessing QoL in prostate cancer patients. The decision to use the FACT-P or the EORTC QLQ-PR25 instrument may depend on the population and aims of the proposed study. Given substantial advancements in treatment and patient care in prostate cancer since the initial development of the FACT-P and EORTC QLQ-PR25, these quality of life instruments should undergo comprehensive validation to ensure they remain a relevant and effective tool for contemporary prostate cancer clinical trials.
RECENT FINDINGS: Thirteen studies published between 2013 and 2022 met the inclusion criteria. FACT-P and EORTC QLQ-PR25 are both validated, reliable, and responsive instruments for assessing QoL in prostate cancer patients. FACT-P emphasizes emotional, social, and functional well-being alongside prostate-specific concerns, while EORTC QLQ-PR25 focuses on prostate-specific symptoms, particularly urinary, sexual, and hormonal function.
SUMMARY: The FACT-P and EORTC QLQ-PR25 are valid tools for assessing QoL in prostate cancer patients. The decision to use the FACT-P or the EORTC QLQ-PR25 instrument may depend on the population and aims of the proposed study. Given substantial advancements in treatment and patient care in prostate cancer since the initial development of the FACT-P and EORTC QLQ-PR25, these quality of life instruments should undergo comprehensive validation to ensure they remain a relevant and effective tool for contemporary prostate cancer clinical trials.